Jahnke K, Korfel A, Martus P, Weller M, Herrlinger U, Schmittel A et al (2005) High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 16(3):445–449. https://doi.org/10.1093/annonc/mdi075

Article  CAS  PubMed  Google Scholar 

Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD (2016) Preventing and managing toxicities of high-dose methotrexate. Oncologist 21(12):1471–1482. https://doi.org/10.1634/theoncologist.2015-0164

Article  CAS  PubMed  PubMed Central  Google Scholar 

Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH et al (1994) Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 12(8):1667–1672. https://doi.org/10.1200/JCO.1994.12.8.1667

Article  CAS  PubMed  Google Scholar 

Alsdorf WH, Karagiannis P, Langebrake C, Bokemeyer C, Frenzel C (2021) Standardized supportive care documentation improves Safety of High-Dose Methotrexate Treatment. Oncologist 26(2):e327–e32. https://doi.org/10.1002/onco.13603

Article  CAS  PubMed  Google Scholar 

May J, Carson KR, Butler S, Liu W, Bartlett NL, Wagner-Johnston ND (2014) High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. Leuk Lymphoma 55(6):1345–1349. https://doi.org/10.3109/10428194.2013.840780

Article  CAS  PubMed  Google Scholar 

Jian C, Chen S, Wang Z, Zhou Y, Zhang Y, Li Z et al (2023) Predicting delayed methotrexate elimination in pediatric acute lymphoblastic leukemia patients: an innovative web-based machine learning tool developed through a multicenter, retrospective analysis. BMC Med Inf Decis Mak 23(1):148. https://doi.org/10.1186/s12911-023-02248-7

Article  Google Scholar 

Zhang W, Zhang Q, Zheng TT, Zhen JC, Niu XH (2016) Delayed high-dose methotrexate excretion and influencing factors in Osteosarcoma patients. Chin Med J (Engl) 129(21):2530–2534. https://doi.org/10.4103/0366-6999.192781

Article  CAS  PubMed  Google Scholar 

Zhan M, Chen Z, Ding C, Qu Q, Wang G, Liu S et al (2021) Risk prediction for delayed clearance of high-dose methotrexate in pediatric hematological malignancies by machine learning. Int J Hematol 114(4):483–493. https://doi.org/10.1007/s12185-021-03184-w

Article  CAS  PubMed  Google Scholar 

Xu WQ, Zhang LY, Chen XY, Pan BH, Mao JQ, Song H et al (2014) Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies. Cancer Chemother Pharmacol 73(1):79–86. https://doi.org/10.1007/s00280-013-2319-2

Article  CAS  PubMed  Google Scholar 

Kataoka T, Sakurashita H, Kajikawa K, Saeki Y, Taogoshi T, Matsuo H (2021) Low serum albumin level is a risk factor for delayed Methotrexate Elimination in High-Dose Methotrexate Treatment. Ann Pharmacother 55(10):1195–1202. https://doi.org/10.1177/1060028021992767

Article  CAS  PubMed  Google Scholar 

Reiss SN, Buie LW, Adel N, Goldman DA, Devlin SM, Douer D (2016) Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Ann Hematol 95(12):2009–2015. https://doi.org/10.1007/s00277-016-2795-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Evans WE, Pratt CB (1978) Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 23(1):68–72. https://doi.org/10.1002/cpt197823168

Article  CAS  PubMed  Google Scholar 

Mosleh E, Snyder S, Wu N, Willis DN, Malone R, Hayashi RJ (2023) Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients. Front Oncol 13:1280587. https://doi.org/10.3389/fonc.2023.1280587

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H et al (2009) Co-administration of Proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 67(1):44–49. https://doi.org/10.1111/j.1365-2125.2008.03303.x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramsey LB, Panetta JC, Smith C, Yang W, Fan Y, Winick NJ et al (2013) Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 121(6):898–904. https://doi.org/10.1182/blood-2012-08-452839

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taylor ZL, Vang J, Lopez-Lopez E, Oosterom N, Mikkelsen T, Ramsey LB (2021) Systematic review of pharmacogenetic factors that Influence High-Dose Methotrexate Pharmacokinetics in Pediatric malignancies. Cancers (Basel) 13(11). https://doi.org/10.3390/cancers13112837

Khera S, Sharma G, Negi V, Shaw SC (2022) Hypoalbuminemia and not undernutrition predicts high-dose methotrexate-induced nephrotoxicity in children with acute lymphoblastic leukemia in resource-constrained centers. Pediatr Blood Cancer 69(9):e29738. https://doi.org/10.1002/pbc.29738

Article  CAS  PubMed  Google Scholar 

Nakano T, Kobayashi R, Matsushima S, Hori D, Yanagi M, Suzuki D et al (2021) Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma. Int J Hematol 113(5):744–750. https://doi.org/10.1007/s12185-020-03071-w

Article  CAS  PubMed  Google Scholar 

Joannon P, Oviedo I, Campbell M, Tordecilla J (2004) High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer 43(1):17–22. https://doi.org/10.1002/pbc.20032

Article  PubMed  Google Scholar 

Gros L, Roldan A, Cabero-Martinez A, Dominguez-Pinilla N, de la Fuente A, Gonzalez-Barca E et al (2023) Incidence and management of patients with methotrexate delayed elimination in the clinical practice: a Delphi study. J Oncol Pharm Pract 29(4):794–801. https://doi.org/10.1177/10781552221079568

Article  CAS  PubMed  Google Scholar 

Latcha S, Gupta M, Lin IH, Jaimes EA (2023) High Dose Methotrexate-Induced Acute kidney Injury: incidence, risk factors, and recovery. Kidney Int Rep 8(2):360–364. https://doi.org/10.1016/j.ekir.2022.10.029

Article  PubMed  Google Scholar 

Aronoff GR (2005) Dose adjustment in renal impairment: response from Drug Prescribing in Renal failure. BMJ 331(7511):293–294. https://doi.org/10.1136/bmj.331.7511.293-a

Article  PubMed  PubMed Central  Google Scholar 

Kawaguchi S, Fujiwara SI, Murahashi R, Nakashima H, Matsuoka S, Ikeda T et al (2021) Risk factors for high-dose methotrexate-induced nephrotoxicity. Int J Hematol 114(1):79–84. https://doi.org/10.1007/s12185-021-03132-8

Article  CAS  PubMed  Google Scholar 

Nirenberg A, Mosende C, Mehta BM, Gisolfi AL, Rosen G (1977) High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat Rep 61(5):779–783

CAS  PubMed  Google Scholar 

Kellum JA, Lameire N, Group KAGW (2013) Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care 17(1):204. https://doi.org/10.1186/cc11454

Article  PubMed  PubMed Central  Google Scholar 

Green MR, Chowdhary S, Lombardi KM, Chalmers LM, Chamberlain M (2006) Clinical utility and pharmacology of high-dose methotrexate in the treatment of primary CNS lymphoma. Expert Rev Neurother 6(5):635–652

Article  CAS  PubMed  Google Scholar 

Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M et al (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374(9700):1512–1520. https://doi.org/10.1016/S0140-6736(09)61416-1

Article  CAS  PubMed  Google Scholar 

Thomas DA, Faderl S, O’Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G et al (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106(7):1569–1580.